Matthew Call
Chief Operating Officer chez ITEOS THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Matthew A.
Call is currently the Chief Operating Officer at iTeos Therapeutics SA and iTeos Therapeutics, Inc. He previously worked as the Director of Business Development at Endocyte, Inc. and held positions as a Principal at First Data Corp., GE Aerospace, HP, Inc., and Disney Enterprises, Inc. Mr. Call completed his undergraduate degree at Brigham Young University and earned an MBA from Purdue University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ITEOS THERAPEUTICS, INC.
0,38% | 05/12/2023 | 137 898 ( 0,38% ) | 2 M $ | 31/03/2024 |
Postes actifs de Matthew Call
| Sociétés | Poste | Début |
|---|---|---|
| ITEOS THERAPEUTICS, INC. | Chief Operating Officer | 01/08/2019 |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Chief Operating Officer | 13/08/2019 |
Anciens postes connus de Matthew Call
| Sociétés | Poste | Fin |
|---|---|---|
| ENDOCYTE, INC. | Chief Operating Officer | - |
Disney Enterprises, Inc.
 Disney Enterprises, Inc. Movies/EntertainmentConsumer Services Disney Enterprises, Inc. owns and operates motion pictures, television shows, music, and computer games. It provides animated characters that appear in Disney cartoons, television shows and feature-length motion pictures like Finding Nemo and The Incredibles including Mickey Mouse, Donald Duck, Winnie the Pooh, Buzz Lightyear, Ariel, Aladdin, Timon, and Pumbaa. The company was founded in 1996 and is located in Burbank, CA. | Corporate Officer/Principal | - |
| GE AEROSPACE | Corporate Officer/Principal | - |
| FIRST DATA CORPORATION | Corporate Officer/Principal | - |
| HP INC. | Corporate Officer/Principal | - |
Formation de Matthew Call
| Brigham Young University | Undergraduate Degree |
| Purdue University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GE AEROSPACE | Producer Manufacturing |
| HP INC. | Electronic Technology |
| ITEOS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
First Data Corp.
 First Data Corp. Regional BanksFinance First Data Corp. provides electronic commerce and payment solutions. It offers credit card processing and solutions, cash advance, data security, payroll delivery, and check acceptance services. The company was founded in 1971 and is headquartered in Atlanta, GA. | Finance |
Disney Enterprises, Inc.
Disney Enterprises, Inc. Movies/EntertainmentConsumer Services Disney Enterprises, Inc. owns and operates motion pictures, television shows, music, and computer games. It provides animated characters that appear in Disney cartoons, television shows and feature-length motion pictures like Finding Nemo and The Incredibles including Mickey Mouse, Donald Duck, Winnie the Pooh, Buzz Lightyear, Ariel, Aladdin, Timon, and Pumbaa. The company was founded in 1996 and is located in Burbank, CA. | Consumer Services |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
